bempedoic acid / CSCs Cancer Research Results

Bempedoic acid — Bempedoic acid is a synthetic, orally administered small-molecule prodrug that is converted by very long-chain acyl-CoA synthetase 1 (ACSVL1/SLC27A2) to an active CoA thioester that inhibits ATP-citrate lyase (ACLY), thereby reducing cytosolic acetyl-CoA supply for cholesterol synthesis and de novo lipogenesis. It is formally classified as an approved lipid-lowering drug and first-in-class ACLY inhibitor; standard abbreviations include BA and BemA. Its established clinical use is cardiovascular/metabolic rather than oncologic, and its cancer relevance is currently mechanistic/preclinical, centered on tumor lipid-metabolism dependence and context-dependent immune effects. Bempedoic acid (ETC-1002) is a small molecule intended to lower LDL-C in hypercholesterolemic patients

Primary mechanisms (ranked):

1. ACLY inhibition with reduced cytosolic acetyl-CoA generation, lowering sterol and fatty-acid biosynthetic flux.
2. Suppression of de novo lipogenesis and membrane-building/anabolic support required by proliferating cancer cells.
3. Downstream growth inhibition and apoptosis in some tumor models, including reduced invasion in selected breast and pancreatic cell systems.
4. Immune-context modulation: ACLY inhibition can increase PUFA peroxidation, mitochondrial stress, cGAS-STING signaling, and PD-L1 expression, which may either hinder monotherapy efficacy or create combination opportunities with checkpoint blockade depending on model context.
5. Secondary hepatocyte-linked AMPK/ACC modulation has been reported, but this is not yet the most reliable cancer-facing primary axis.

Bioavailability / PK relevance: Oral once-daily drug; FDA labeling states median Tmax is about 3.5 hours, food does not meaningfully affect oral bioavailability, plasma protein binding is very high (~99.3%), and mean half-life is about 21 hours. A key delivery constraint is biologic activation: bempedoic acid requires ACSVL1-mediated CoA conversion, with activation primarily in liver and limited activity expected in tissues lacking that enzyme, so tumor responsiveness is likely expression-context dependent rather than simply dose dependent.

In-vitro vs systemic exposure relevance: Many mechanistic oncology studies use about 25–30 µM. Reported human total Cmax is in the same broad range, but the drug is highly protein bound and antitumor activity additionally depends on cellular activation to bempedoyl-CoA, so nominal in-vitro concentrations can overstate broadly achievable free/active exposure in tumors. This is therefore not a clean “plasma concentration equals tumor effect” agent.

Clinical evidence status: Approved drug with strong cardiovascular RCT evidence, but cancer evidence remains preclinical and combination-hypothesis generating. No established oncology indication and no clear oncology trial program was identified in current major registry searches.

Mechanistic profile